Candel Therapeutics presents ASTRO 2026 prostate cancer data
Candel Therapeutics said new data at ASTRO 2026 showed sustained immune remodeling more than two years after aglatimagene besadenovec treatment in localized prostate cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.